Method Of Altering The Differentiation State Of The Cell Patents (Class 435/377)
-
Publication number: 20150017131Abstract: The present invention recognizes that there exists a long felt need for reliable hair growth methods and compositions that do not suffer from side effects and limitations of current technologies, such as surgery using a subject's own hair and pharmaceutical compositions. A first aspect of the present invention is a method of making at least one three dimensional collection of cells capable of forming a functional hair follicle. A second aspect of the present invention is a product produced by the method of making at least one three dimensional collection of cells capable of forming a functional hair follicle of the present invention. A third aspect of the present invention is a method of making at least one functional hair follicle. A fourth aspect of the present invention is a product produced by the method of making at least one functional hair follicle of the present invention.Type: ApplicationFiled: June 19, 2014Publication date: January 15, 2015Inventor: Jordan FABRIKANT
-
Publication number: 20150017718Abstract: The present invention relates to a method for inducing cardiac differentiation of a pluripotent stem cell, which comprises the steps of (1) culturing a pluripotent stem cell in a medium containing one or more WNT signaling activators, and (2) culturing a cell produced in the step (1) in a medium containing one or more WNT signaling inhibitor.Type: ApplicationFiled: January 25, 2013Publication date: January 15, 2015Inventors: Norio Nakatsuji, Itsunari Minami, Motonari Uesugi, Kazuhiro Aiba
-
Publication number: 20150017674Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into vascular bed cells. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into vascular bed cells based on linked steps of chemically defined medium inductions.Type: ApplicationFiled: December 9, 2013Publication date: January 15, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Klaus Christensen, Martin Graf, Roberto Iacone, Christoph Patsch, Eva Christina Thoma
-
Publication number: 20150017134Abstract: In some aspects, compositions and methods useful for generating stem cells from epithelial cells are disclosed.Type: ApplicationFiled: March 1, 2013Publication date: January 15, 2015Inventors: Wenjun Guo, Robert A. Weinberg, Zuzana Keckesova
-
Publication number: 20150017723Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.Type: ApplicationFiled: April 23, 2012Publication date: January 15, 2015Inventors: Cliona M. Rooney, Ann M. Leen, Juan F. Vera, Minhtran V. Ngo, Rainer Ludwig Knaus
-
Publication number: 20150017139Abstract: The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.Type: ApplicationFiled: July 18, 2014Publication date: January 15, 2015Inventors: Yadong Huang, Karen Ring
-
Publication number: 20150017724Abstract: This invention relates, e.g., to a method for differentiating mammalian (e.g., human) pluripotent stem cells (PSCs) into endothelial cells (ECs) in vitro, by plating a single-cell suspension of PSCs onto a suitable surface such as type IV collagen and culturing the cells with VEGF after which ECs can be harvested. A preferred embodiment of the method first cultures the cells without VEGF and then sequentially cultures the cells with VEGF. Differentiation can be enhanced by adding an inhibitor of transforming growth factor ? to the culturing with VEGF.Type: ApplicationFiled: February 28, 2013Publication date: January 15, 2015Inventors: Sharon Gerecht, Sravanti Kusuma
-
Patent number: 8932856Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: GrantFiled: October 5, 2012Date of Patent: January 13, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Patent number: 8932855Abstract: A method of treating cancer in a patient comprises immortalizing B cells collected from the patient by infection with Epstein Barr virus, transforming the cells to a latent stage, culturing the cells in the presence of a cancer antigen, harvesting exosomes released from the cells, administering the exosomes to the patient. Alternatively the harvested exosomes are loaded with cancer antigen.Type: GrantFiled: July 2, 2010Date of Patent: January 13, 2015Assignee: ITH Immune Therapy Holdings ABInventor: Susanne Gabrielsson
-
Patent number: 8932853Abstract: The present invention provides a method of more efficiently producing pancreas cells, particularly pancreatic hormone-producing cells, a method of stably producing pancreas cells in a large amount by more efficiently inducing differentiation of stem cells into pancreas cells, a medicament containing a pancreas cells and a screening method using the cells.Type: GrantFiled: December 28, 2010Date of Patent: January 13, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Masaki Hosoya, Yuya Kunisada, Masanobu Shoji, Noriko Yamazoe
-
Patent number: 8933049Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.Type: GrantFiled: February 20, 2013Date of Patent: January 13, 2015Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Rachel Siegel, Joyce Eskdale, Adam Swider
-
Patent number: 8932857Abstract: The present invention provides a method for selecting human induced pluripotent stem (iPS) cells which can be safely used for transplantation. That is, the present invention provides a method for selecting human iPS cells having reduced differentiation resistance, comprising the steps of: (1) inducing differentiation of human iPS cells; (2) detecting remaining undifferentiated cells after the step (1); and (3) selecting human iPS cells whose rate of remaining undifferentiated cells detected in step (2) is equivalent to or not more than that of control cells.Type: GrantFiled: June 15, 2011Date of Patent: January 13, 2015Assignee: Kyoto UniversityInventors: Shinya Yamanaka, Kazutoshi Takahashi, Mari Ohnuki
-
Publication number: 20150011003Abstract: A medium which comprises a fibroblast growth factor (FGF), and a sulfated compound or a pharmaceutically acceptable salt thereof at a concentration which promotes the growth of a stem cell in the presence of FGF, is useful for culturing stem cells.Type: ApplicationFiled: September 26, 2014Publication date: January 8, 2015Applicant: AJINOMOTO CO., INC.Inventors: Yoko KURIYAMA, Nao SUGIMOTO, Manabu KITAZAWA, Satoru OKAMOTO, Sho SENDA, Ikue HARATA, Satoru OHASHI
-
Publication number: 20150010583Abstract: The present invention relates to the ex vivo differentiation of NK cells from CD34+ hematopoietic stem cells. Such NK cells and their progenitor cells can be used in therapies of a broad range of malignancies. In the present invention it is shown that IL-12 modulates ex vivo NK cell differentiation. Specific, we achieved significantly higher expression of KIR, CD16 and CD62L in the presence of IL-12 in the cell culture system. The induction of receptor expression by IL-12 occurred predominantly on an augmented population of CD33+NKG2A+ NK cells early during NK cell differentiation. These cells further show enhanced cytolytic activity against MHC class I positive AML targets. In line with the enhanced CD16 expression, IL-12 modulated ex vivo generated NK cells exhibit an improved antibody-dependent-cytotoxicity, using anti CD20 antibody on various B cell targets. Additional to the enhanced expression of CD62L, we show that this cell population consists of a specific chemokine receptor profile.Type: ApplicationFiled: February 7, 2013Publication date: January 8, 2015Applicant: IPD-Therapeutics B.V.Inventor: Jan Spanholtz
-
Publication number: 20150010515Abstract: The present invention relates to a method for producing mammalian neural plate border stem cells (NPBSCs), comprising: (a) differentiation of mammalian pluripotent stem cells by (a-i) culturing mammalian pluripotent stem cells in pluripotent stem cell medium for about 24 to about 96 hours, wherein the pluripotent stem cell medium comprises: (i) an inhibitor of the activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-ii) culturing the cells obtained in step (a-i) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an inhibitor of the Activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-iii) culturing the cells obtained in step (a-ii) for about 24 toType: ApplicationFiled: January 11, 2013Publication date: January 8, 2015Inventors: Hans R. Schoeler, Jared L. Sterneckert, Michael Glatza, Peter Reinhardt
-
Publication number: 20150010607Abstract: The invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.Type: ApplicationFiled: February 7, 2013Publication date: January 8, 2015Inventors: Michael Francis, Roy Ogle
-
Publication number: 20150011609Abstract: The present invention discloses a set of human microRNAs, or a primary transcript for such microRNAs, or a precursor of such microRNAs, or a mimic of such microRNAs or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening microRNAs and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes.Type: ApplicationFiled: December 21, 2012Publication date: January 8, 2015Inventors: Mauro Giacca, Serena Zacchigna, Miguel Luis Cunha Mano, Ana Sofia Bregieiro Eulalio
-
Publication number: 20150010514Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.Type: ApplicationFiled: November 2, 2012Publication date: January 8, 2015Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
-
Patent number: 8927281Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.Type: GrantFiled: October 29, 2009Date of Patent: January 6, 2015Assignees: IRM LLC, The Scripps Research InstituteInventors: Anthony E. Boitano, Michael Cooke, Shifeng Pan, Peter G. Schultz, John Tellew, Yongqin Wan, Xing Wang
-
Patent number: 8927278Abstract: The present invention develops a straightforward and rapid method for generating immunomodulatory cells from peripheral mononuclear cells, comprising treating peripheral mononuclear cells with a hepatocyte growth factor (HGF) to induce differentiation of the peripheral mononuclear cells into immunomodulatory leukocytes. The present invention also provides an immunomodulatory cell prepared according to this method. The present invention further provides a method for treating a disease caused by abnormal immune response comprising administering a HGF to a patient exhibiting the disease, inducing the patient's peripheral mononuclear cells to differentiate into immunomodulatory leukocytes, and modulating the abnormal immune response.Type: GrantFiled: September 10, 2012Date of Patent: January 6, 2015Assignee: National Health Research InstitutesInventors: Lin-Ju Yen, Ko-Jiunn Liu, Huey-Kang Sytwu
-
Patent number: 8926964Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: GrantFiled: July 13, 2011Date of Patent: January 6, 2015Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Patent number: 8927277Abstract: Provided are a method of improving the efficiency of establishment of iPS cells, comprising the step of contacting one or more substances selected from the group consisting of members of the GLIS family (e.g., GLIS1) and nucleic acids that encode the same and one or more substances selected from the group consisting of members of the Klf family and nucleic acids that encode the same, with a somatic cell, an iPS cell comprising an exogenous nucleic acid that encodes a member of the GLIS family or a member of the Klf family, that can be obtained by the method, and a method of producing a somatic cell by inducing the differentiation of the iPS cell.Type: GrantFiled: February 16, 2011Date of Patent: January 6, 2015Assignees: Kyoto University, National Institute of Advanced Industrial Science and Technology, Japan Biological Informatics ConsortiumInventors: Shinya Yamanaka, Naoki Goshima, Momoko Maekawa, Yoshifumi Kawamura, Hiromi Mochizuki
-
Patent number: 8927273Abstract: The present invention provides a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.Type: GrantFiled: August 19, 2004Date of Patent: January 6, 2015Assignee: Takara Bio Inc.Inventors: Mitsuko Ideno, Nobuko Muraki, Kinuko Ogawa, Masayuki Kishimoto, Tatsuji Enoki, Hiroaki Sagawa, Ikunoshin Kato
-
Patent number: 8927519Abstract: Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided.Type: GrantFiled: January 27, 2014Date of Patent: January 6, 2015Assignee: City of HopeInventors: John J. Rossi, Nan-Sook Lee
-
Patent number: 8927515Abstract: This invention relates to compounds, compositions, and methods useful for reducing AR target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.Type: GrantFiled: December 21, 2012Date of Patent: January 6, 2015Assignee: Dicerna Pharmaceuticals, Inc.Inventors: Bob D. Brown, Henryk T. Dudek
-
Patent number: 8927274Abstract: A method of generating pancreatic progenitor cells is disclosed. The method comprises: (a) differentiating stem cells under conditions such that at least a portion of the cells express glucose transporter 2 (GLUT2) so as to generate GLUT2-expressing cells; and (b) enriching for the GLUT2-expressing cells so as to generate a population of GLUT2 enriched cells, wherein at least 80% of the population of GLUT2 enriched cells express GLUT2, thereby generating pancreatic progenitor cells. Isolated populations of cells generated according to the method, pharmaceutical compositions comprising same and uses thereof are also disclosed.Type: GrantFiled: April 12, 2011Date of Patent: January 6, 2015Assignee: Technion Research & Development Foundation LimitedInventors: Joseph Itskovitz-Eldor, Bettina Fishman, Hanna Segev
-
Patent number: 8927280Abstract: Certain embodiments disclosed herein are directed to a method of producing endoderm cells, such as definitive endoderm cells by exposing stem cells such as embryonic stem cells or induced pluripotent stem (iPS) cells to an effective amount of at least one compound described herein to differentiate the stem cells into the endoderm cells such as definitive endoderm cells. Differentiated endoderm cells produced by the methods disclosed herein can be differentiated into pancreatic epithelium, and other endoderm derivatives such as thymus, liver, stomach, intestine and lung. Another aspect of the present invention relates to a method of producing pancreatic progenitor cells, such as Pdx1-positive pancreatic progenitor cells by exposing endoderm cells, such as definitive endoderm cells to an effective amount of at least one compound described herein to differentiate the definitive endoderm cells into Pdx1-positive pancreatic progenitor cells.Type: GrantFiled: August 12, 2013Date of Patent: January 6, 2015Assignee: President and Fellows of Harvard CollegeInventors: Douglas A. Melton, Malgorzata Borowiak, Rene Maehr, Shuibing C. Chen, Weiping Tang, Julia L. Fox, Stuart L. Schreiber
-
Patent number: 8927279Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: GrantFiled: October 5, 2012Date of Patent: January 6, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Publication number: 20150004146Abstract: Methods of culturing mesenchymal stem cells are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide and fibroblast growth factor 4 (FGF4). Populations of mesenchymal stem cells generated using the methods described herein and uses thereof are also provided.Type: ApplicationFiled: February 13, 2012Publication date: January 1, 2015Applicant: Gamida-Cell Ltd.Inventors: Tony Peled, Yair Steinhardt
-
Publication number: 20150004701Abstract: The present invention relates to a method for differentiating stem cells into neurons, and is characterized in that stem cells are treated with a culture additive comprising lipoic acid, albumin, hydrocortisone, and insulin after culturing for differentiation into neurons. Since the neurons produced according to the method for producing neurons of the present invention express nestin, neuroD1, neuron-specific enolase (NSE), neurofilament (NF), tau, microtubule-associated protein 2 (MAP2), and doublecortin (DCX), just as normal mature neurons do, the neurons of the present invention can be effectively used in various therapeutic agents for neurons and as cell origins for an in vitro study system.Type: ApplicationFiled: February 5, 2013Publication date: January 1, 2015Inventors: Jung Keug Park, Hee Hoon Yoon, Soo Yeon Kim, Young Kwon Seo
-
Publication number: 20150005370Abstract: The present invention discloses the use of a human NLK gene and associated drugs thereof. The present invention discloses the use of the NLK gene for tumor treatment, tumor diagnosis and drug preparation. The present invention further constructs an isolated molecule that attenuates expression of the NLK gene of tumor cells, cells comprising the isolated molecule and a NLK interference lentivirus, and discloses the use thereof as well. The isolated molecule or the NLK interference lentivirus that attenuates expression of the NLK gene provided in the present invention can specifically attenuate expression of the human NLK gene, especially the lentivirus, can effectively infect target cells, efficiently inhibit the expression of the NLK gene in target cells, and inhibit the growth of tumor cells, thus has great significance in tumor treatment.Type: ApplicationFiled: January 18, 2012Publication date: January 1, 2015Applicant: SHANGHAI GENECHEM CO., LTDInventors: Haixiong Han, Xiangying Zhu, Qin Sun, Xuefeng Gu, Shenghua Xie, Yang Li, Yangsheng Jin, Honghua Qu, Yueqiong Cao
-
Publication number: 20150004612Abstract: A method of generating an induced progenitor population (iPP) of cells and/or induced population of cells from somatic cells, comprising the steps: a) obtaining a starting cell population, wherein cells of the starting cell population comprise, or are contacted with, a nucleic acid molecule encoding four reprogramming factors under the control of a control element, wherein the four reprogramming factors are optionally Oct4, Klf4, Sox2 and c-Myc, and wherein the control element prevents or stops expression of the reprogramming factors under its control in the absence of induction by an inducing agent; and b) transiently inducing expression of the reprogramming factors in the starting cell population to obtain an iPP, c) optionally isolating the iPP, and d) terminating the transient induction while the proliferative capacity of the iPP remains under the control of the one or more exogenous reprogramming factors to produce an induced population of cells.Type: ApplicationFiled: June 3, 2014Publication date: January 1, 2015Inventors: Thomas K. Waddell, Li Guo, Andras Nagy
-
Publication number: 20150004700Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: ApplicationFiled: April 29, 2014Publication date: January 1, 2015Applicant: ALEXION PHARMACEUTICALS, INC.Inventors: Katherine S. BOWDISH, Shana FREDERICKSON, Mark RENSHAW
-
Publication number: 20150005361Abstract: Disclosed herein are compositions and methods to treat and reduce therapeutic resistance in chronic myelogenous leukemia. Also disclosed herein are methods to generate leukemia stem cell like cells (iLSCs) generated from CML patient-derived iPSCs, and methods for utilizing iLSCs in screens to identify modulators of CML drug resistance and gene targets that underlie CML drug resistance.Type: ApplicationFiled: April 11, 2014Publication date: January 1, 2015Applicant: Wisconsin Alumni Research FoundationInventors: Igor I. Slukvin, Kran Suknuntha
-
Publication number: 20150004144Abstract: The technology described herein is directed to methods and compositions relating to the differentiation and activity of brown adipocytes, and the therapeutic uses thereof.Type: ApplicationFiled: November 28, 2012Publication date: January 1, 2015Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Chad Cowan, Robert Schinzel, Tim Ahfeldt, YounKyoung Lee
-
Publication number: 20150004145Abstract: The disclosure relates to the development of methods for making hematopoietic stem cells from differentiated cells by introducing and expressing transcription factors. More particularly, the disclosure provides methods for redirecting differentiated cells to a hematopoietic stem cell state or to a hemogenic endothelial cell state by direct programming with specific combinations of transcription factors.Type: ApplicationFiled: January 30, 2013Publication date: January 1, 2015Inventors: Ihor R. Lemischka, Kateri Moore, Carlos Filipe Pereira
-
Patent number: 8921103Abstract: Compositions and methods for creating a laminar construct for tissue-engineered dermal equivalent are provided. One composition provided herein comprises a hydrogel matrix comprising two or more hydrogels layers and a population of stem cells. Associated methods are also provided.Type: GrantFiled: August 27, 2010Date of Patent: December 30, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Laura Suggs, Shanmugasundaram Natesan, Ge Zhang, Robert J. Christy, Thomas Walters
-
Publication number: 20140377840Abstract: A nucleic acid sequence, including an isolated, purified or recombinant nucleic acid sequence, includes: (a) a nucleic acid sequence encoding a polypeptide for stimulating embryonic development, namely, a PLC-zeta; PLC? amino acid sequence, capable of triggering calcium oscillations in oocytes; (b) a sequence substantially homologous to or that hybridizes to sequence (a) under stringent conditions; (c) a sequence substantially homologous to or that hybridizes to the sequences (a) or (b) but for degeneracy of the genetic code; and (d) an oligonucleotide specific for any of the sequences (a), (b) or (c) above.Type: ApplicationFiled: April 14, 2014Publication date: December 25, 2014Inventor: Francis Anthony Lai
-
Publication number: 20140377865Abstract: This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.Type: ApplicationFiled: January 13, 2014Publication date: December 25, 2014Applicant: ADVANCED CELL TECHNOLOGY, INC.Inventors: ROBERT P. LANZA, YOUNG GIE CHUNG
-
Publication number: 20140377233Abstract: The present invention is directed to a method of preparing an artificial tooth primordium in vitro, comprising the steps: a) providing isolated mesenchymal dental pulp cells; and b) culturing the mesenchymal dental pulp cells under non-adherent conditions to form a cell aggregate representing an artificial tooth primordium; as well as to an artificial tooth primordium derived therefrom.Type: ApplicationFiled: February 20, 2013Publication date: December 25, 2014Inventors: Roland Lauster, Uwe Marx, Jennifer Binder, Mark Rosowski
-
Publication number: 20140377299Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.Type: ApplicationFiled: August 4, 2014Publication date: December 25, 2014Applicant: LIFE SCIENCES RESEARCH PARTNERS VZWInventor: Jean-Marie SAINT-REMY
-
Publication number: 20140377231Abstract: The present disclosure concerns methods and compositions for differentiating cells, including adipose cells, into chondrocyte-like cells via in vitro, ex vivo, and/or in vivo mechanical strain. In particular aspects, adipose cells or re-differentiated adipose cells that are chondrocyte-like cells, are delivered to a joint or are shaped into cartilage. In some embodiments, the adipose cells may be delivered to a joint, such as an intervertebral disc, following which the cells differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. In certain aspects, the cells prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example.Type: ApplicationFiled: June 13, 2014Publication date: December 25, 2014Inventor: Pete O'Heeron
-
Publication number: 20140377832Abstract: The invention relates to induction of reprogramming of somatic cells, by methods which require mild growth conditions. Disclosed are methods of inducing dedifferentiation of mesenchymal stromal cell (MSC), by seeding or incubating mesenchymal stromal cells (MSCs) at low density, and without introduction or expression of exogenous genes in the cells.Type: ApplicationFiled: January 14, 2013Publication date: December 25, 2014Inventors: Dov Zipori, Ofer Shoshani
-
Publication number: 20140377234Abstract: The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.Type: ApplicationFiled: September 9, 2014Publication date: December 25, 2014Inventors: Timothy C. Fong, Adrianus Geertrudis Wilhelmus Domen, Julie Lynne Christiansen
-
Publication number: 20140370044Abstract: The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.Type: ApplicationFiled: January 30, 2013Publication date: December 18, 2014Inventor: Jean-Marie Saint-Remy
-
Publication number: 20140369973Abstract: The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits.Type: ApplicationFiled: December 7, 2012Publication date: December 18, 2014Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER, RESEARCH FOUNDATION (GNF)Inventors: Irwin D. Bernstein, Anthony E. Boitano, Michael Cooke
-
Publication number: 20140370014Abstract: Alleviating obesity in a subject (e.g., a human subject) having, being suspected of having, or at risk for obesity using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.Type: ApplicationFiled: June 17, 2014Publication date: December 18, 2014Applicant: National Cheng Kung UniversityInventors: Ming-Shi Chang, Yu-Hsiang Hsu
-
Publication number: 20140369968Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.Type: ApplicationFiled: June 12, 2014Publication date: December 18, 2014Inventors: Igor Slukvin, Akhilesh Kumar
-
Publication number: 20140370007Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.Type: ApplicationFiled: December 6, 2012Publication date: December 18, 2014Applicant: Advanced Cell Technology, Inc.Inventors: Kathryn L. McCabe, Shi-Jiang Lu, Robert P. Lanza
-
Publication number: 20140369971Abstract: The present invention provides a fibromodulin (FMOD) reprogrammed (FReP) cell and a method of making therefor, a culture medium therefor, and a supernatant thereof, and methods of making and using these.Type: ApplicationFiled: October 22, 2012Publication date: December 18, 2014Inventors: B. Chia Soo, Kang Ting, Zhong Zheng